BENITIONSClinical Trial Intelligence

Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients

Фаза 4 Завершено NCT05562063

ЗаболеваниеHeart Failure With Preserved Ejection Fraction
ФазаФаза 4
СпонсорJuan Badimon
СтатусЗавершено
Участники88 участн.
ВмешательствоSotagliflozin
Дата начала26.10.2022
Дата завершения4.06.2025
Публикация результатов24.06.2026

Кратко

The clinical benefits of the dual Sodium-Glucose cotransporter (SGLT) 1 and 2-inhibition have recently been reported in two clinical trials. The SOLOIST reported the benefits of sotagliflozin in Type-2 Diabetes Mellitus (T2DM) patients hospitalized for worsening of Heart Failure (HF), while the SCORED involved T2DM patients with Chronic Kidney Disease (CKD). It is worth noting that not only did the event curves separate within the first week post-treatment, but the effects of sotagliflozin on HF-related outcomes were observed regardless of Left Ventricular Ejection Fraction (LVEF) values and did not seem to attenuate with increasing LVEF as seen with empagliflozin and sacubitril/valsartan. Despite the favorable outcomes, the mechanism(s) of action through which sotagliflozin exerts these benefits remains unclear. The present study aims to investigate the potential (non-glucose dependent) "cardio-renal" pleiotropic effects of sotagliflozin in a mechanistic, randomized, double blind, placebo-control trial in HF patients with preserved ejection fraction (HFpEF). Comparisons between treatment groups will be made using cardiac MRI, CPET, 6-MWT and KCCQ-12.

Changes in Left Ventricular Mass in CMRI

Baseline and 6 months · grams

Sotagliflozin-8.6 grams
Placebo5.7 grams

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.